Prevalence of Acute Hypersensitivity Reactions in Pediatric Patients Receiving Crotalidae Polyvalent Immune Fab.
Adolescent
Age Factors
Animals
Antivenins
/ adverse effects
Child
Child, Preschool
Crotalid Venoms
/ antagonists & inhibitors
Crotalinae
Drug Hypersensitivity
/ diagnosis
Female
Humans
Immunoglobulin Fab Fragments
/ adverse effects
Infant
Male
Prevalence
Retrospective Studies
Risk Assessment
Risk Factors
Snake Bites
/ diagnosis
Time Factors
Treatment Outcome
Antivenom
Crotalid
Hypersensitivity reaction
Pediatric
Journal
Journal of medical toxicology : official journal of the American College of Medical Toxicology
ISSN: 1937-6995
Titre abrégé: J Med Toxicol
Pays: United States
ID NLM: 101284598
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
24
02
2020
accepted:
07
07
2020
revised:
29
04
2020
pubmed:
28
7
2020
medline:
5
11
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
Studies of acute hypersensitivity reactions in pediatric populations receiving Crotalidae Polyvalent Immune Fab (CPIF) are complicated by small size, wide age ranges, and diverse definitions of such reactions. This is a retrospective chart review of patients aged 13 years or younger treated with CPIF for Crotalid envenomation from November 2006 to 2016. The primary outcome was the presence of an acute hypersensitivity reaction to CPIF and was defined as the development of any of the following symptoms within 3 hours of initiation of CPIF infusion: urticaria, wheezing or respiratory distress, angioedema, hypotension, nausea, and/or vomiting. Demographics, CPIF dose to control and total dose, bite location, level of care, and length of stay were also recorded. Thirty-four patients were ultimately treated with CPIF. Ages ranged from 10 months to 13 years. Twenty-one patients (60%) were male, 24 (70.6%) were admitted to the ICU, and the median length of stay was 2 days with a range of 1-11 days. Zero patients developed an acute hypersensitivity reaction to CPIF. Acute hypersensitivity reactions to CPIF did not occur in this cohort. Such reactions are rare with the use of CPIF in pediatric patients.
Identifiants
pubmed: 32710249
doi: 10.1007/s13181-020-00798-0
pii: 10.1007/s13181-020-00798-0
pmc: PMC7785595
doi:
Substances chimiques
Antivenins
0
Crotalid Venoms
0
Crotalidae Polyvalent immune Fab
0
Immunoglobulin Fab Fragments
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-50Références
Arch Intern Med. 2001 Sep 10;161(16):2030-6
pubmed: 11525706
Clin Toxicol (Phila). 2009 Apr;47(4):327-35
pubmed: 19514880
Clin Pediatr (Phila). 2012 Oct;51(10):945-9
pubmed: 22511193
Pediatrics. 2002 Nov;110(5):968-71
pubmed: 12415038
Ann Emerg Med. 2002 Jun;39(6):609-15
pubmed: 12023703
Acad Emerg Med. 2007 Apr;14(4):373-6
pubmed: 17296804
Ann Emerg Med. 1997 Jul;30(1):33-9
pubmed: 9209222